These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 30325490)
1. Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphism. Charfi R; Mzoughi K; Boughalleb M; Hosni H; Kouidhi S; Sfar I; Hammami N; Zaïri I; Limam M; Zedini C; Mrabet A; Klouz A; Gorgi Y; Kharrat M; Baccar H; Trabelsi S Tunis Med; 2018 Mar; 96(3):209-218. PubMed ID: 30325490 [TBL] [Abstract][Full Text] [Related]
2. The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention. Ayesh BM; Al-Astal IR; Yassin MM Int J Clin Pharm; 2019 Feb; 41(1):96-103. PubMed ID: 30656556 [TBL] [Abstract][Full Text] [Related]
3. Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents. Tan SSN; Fong AYY; Mejin M; Gerunsin J; Kong KL; Chin FYY; Tiong LL; Lim MSH; Asri S; Khiew NZ; Voon CY; Mohd Amin NH; Cham YL; Koh KT; Oon YY; Ong TK Pharmacogenomics; 2017 Aug; 18(13):1225-1239. PubMed ID: 28745576 [TBL] [Abstract][Full Text] [Related]
4. The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention. Zhang Z; Chen M; Zhang L; Zhao Q BMC Pharmacol Toxicol; 2020 Jan; 21(1):1. PubMed ID: 31900240 [TBL] [Abstract][Full Text] [Related]
5. Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype? Chouchene S; Dabboubi R; Raddaoui H; Abroug H; Ben Hamda K; Hadj Fredj S; Abderrazak F; Gaaloul M; Rezek M; Neffeti F; Hellara I; Sassi M; Khefacha L; Sriha A; Nouira S; Najjar MF; Maatouk F; Messaoud T; Hassine M Eur J Clin Pharmacol; 2018 Dec; 74(12):1567-1574. PubMed ID: 30073432 [TBL] [Abstract][Full Text] [Related]
7. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis. Xi Z; Fang F; Wang J; AlHelal J; Zhou Y; Liu W Platelets; 2019; 30(2):229-240. PubMed ID: 29257922 [TBL] [Abstract][Full Text] [Related]
8. CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention. Mohammad AM; Al-Allawi NAS J Cardiovasc Pharmacol; 2018 Jun; 71(6):347-351. PubMed ID: 29554005 [TBL] [Abstract][Full Text] [Related]
9. Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study. Yu L; Wang T; Bai H; Zhu W; Li Y; Wu J; Liu W; Sun L; Yu A; Li H BMC Cardiovasc Disord; 2021 Aug; 21(1):391. PubMed ID: 34384383 [TBL] [Abstract][Full Text] [Related]
10. The prognostic difference study on the individualized clopidogrel administration in Hmong and Dong patients based on the CYP2C19 gene polymorphism after percutaneous coronary intervention. Yuan X; Liu Y; Zhang T; Xia J; Lan X; Pan Q; Han M Cell Mol Biol (Noisy-le-grand); 2024 Sep; 70(8):110-115. PubMed ID: 39262255 [TBL] [Abstract][Full Text] [Related]
11. The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention. Wang T; Li H; Wang F; Sun L; Yu L Eur J Clin Pharmacol; 2021 Nov; 77(11):1679-1686. PubMed ID: 34164723 [TBL] [Abstract][Full Text] [Related]
12. High Frequency of CYP2C19*3 Heterozygotes Among Patients Under Clopidogrel Treatment in Ouagadougou, Burkina Faso. Ouattara AK; Kagambega YD; Ouedraogo TC; Traore L; Ouedraogo M; Yameogo NV; Simpore J Pak J Biol Sci; 2024 Jul; 27(8):398-403. PubMed ID: 39300676 [TBL] [Abstract][Full Text] [Related]
14. Cytochrome P-450 CYP2C19 genetic polymorphism and its relation with clopidogrel resistance. Nawaz U; Noor M; Waheed A J Pak Med Assoc; 2023 Dec; 73(12):2388-2392. PubMed ID: 38083918 [TBL] [Abstract][Full Text] [Related]
15. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608 [TBL] [Abstract][Full Text] [Related]
16. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746 [TBL] [Abstract][Full Text] [Related]